Cargando…
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
Multiple myeloma (MM) is a malignancy of the antibody-producing plasma cells. MM is a highly heterogeneous disease, which has hampered the identification of a common underlying mechanism for disease establishment as well as the development of targeted therapy. Here we present the first genome-wide p...
Autores principales: | Agarwal, Prasoon, Alzrigat, Mohammad, Párraga, Alba Atienza, Enroth, Stefan, Singh, Umashankar, Ungerstedt, Johanna, Österborg, Anders, Brown, Peter J., Ma, Anqi, Jin, Jian, Nilsson, Kenneth, Öberg, Fredrik, Kalushkova, Antonia, Jernberg-Wiklund, Helena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872750/ https://www.ncbi.nlm.nih.gov/pubmed/26755663 http://dx.doi.org/10.18632/oncotarget.6843 |
Ejemplares similares
-
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017) -
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016) -
Polycomb Target Genes Are Silenced in Multiple Myeloma
por: Kalushkova, Antonia, et al.
Publicado: (2010) -
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021) -
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
por: Alzrigat, Mohammad, et al.
Publicado: (2018)